Which is the best combination therapy in relapsed and refractory multiple myeloma?
TGR-1202- a new generation PI3K delta inhibitor for CLL
A follow-up from the CASTOR trial evaluating daratumumab with bortezomib for the treatment of MM
Targeted Antibody Mogamulizumab Superior to Vorinostat for Previously Treated CTCL
Youn H. Kim
Indications for the use of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma